The efficacy of diphtheria-growth factor fusion proteins is enhanced by co-administration of cytosine arabinoside in an immunodeficient mouse model of human acute myeloid leukemia

Donna E. Hogge, Michaela Feuring-Buske, Brigitte Gerhard, Arthur E. Frankel

Research output: Contribution to journalArticle

24 Scopus citations

Abstract

Addition of cytosine arabinoside (Ara-C) to truncated diphtheria toxin (DT388) fused to granulocyte macrophage-colony stimulating factor (GMCSF) or interleukin-3 (IL3) was studied in a NOD/SCID mouse model of human AML. Ara-C alone did not reduce the % human AML cells in mouse bone marrow (BM). DT388IL3 or DT388GMCSF alone reduced but did not eradicate engraftment for two of four and two of three samples, respectively. In contrast, Ara-C with DT388IL3 eliminated AML from mouse BM with one of four samples while DT388GMCSF with Ara-C eliminated or reduced AML cells as compared to mice receiving either agent alone with two of three samples.

Original languageEnglish (US)
Pages (from-to)1221-1226
Number of pages6
JournalLeukemia Research
Volume28
Issue number11
DOIs
StatePublished - Nov 1 2004

Keywords

  • AML
  • Ara-C
  • Diphtheria toxin fusion proteins
  • NOD/SCID mice

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'The efficacy of diphtheria-growth factor fusion proteins is enhanced by co-administration of cytosine arabinoside in an immunodeficient mouse model of human acute myeloid leukemia'. Together they form a unique fingerprint.

  • Cite this